ARA-290
Erythropoietin-Derived Cytoprotective Peptide
ARA-290 is an 11-amino-acid peptide derived from the helix B surface of erythropoietin (EPO). It activates the innate repair receptor (IRR/beta common receptor complex) — a tissue protection pathway present on neurons, immune cells, and most organs — without activating the erythropoietic receptor that drives red blood cell production.
At a Glance
EPO is best known for red blood cell production, but it also activates a separate tissue protection pathway through the beta common receptor (βcR). ARA-290 was engineered to selectively activate this cytoprotective pathway without triggering erythropoiesis — separating EPO's protective effects from its blood-thickening hematopoietic effects.
Phase 2 clinical trials have been conducted in sarcoidosis-associated small fiber neuropathy and diabetic peripheral neuropathy — conditions where nerve protection and repair are the primary research objectives.
Its neuropathic pain research application is one of the most clinically relevant — Phase 2 data in sarcoidosis-related small fiber neuropathy showed significant improvements in pain scores and quality of life measures.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
IRR/βcR Activation
Selectively activates the innate repair receptor complex (βcR + EPO receptor heterodimer) — the tissue protection pathway — without activating the homodimeric EPO receptor responsible for erythropoiesis.
Neuroprotection
Protects small sensory fibers and promotes nerve repair — studied specifically in small fiber neuropathy conditions where conventional treatments fail.
Anti-Inflammatory
Activates anti-inflammatory signaling through βcR on macrophages and other immune cells — reducing tissue-damaging inflammation after injury.
Organ Cytoprotection
βcR is expressed in heart, kidney, brain, and gut — ARA-290's cytoprotective effects extend across multiple organ systems in preclinical models.
Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.
- Small fiber neuropathy — Phase 2 trials in sarcoidosis-associated SFN with significant pain reduction
- Diabetic peripheral neuropathy — nerve protection and repair in high-glucose models
- EPO pathway dissection — cytoprotective vs erythropoietic separation research
- Cardiac cytoprotection — ischemia-reperfusion models
- Renal protection — kidney injury cytoprotection via IRR
- Systemic inflammation — anti-inflammatory without immunosuppression
- Neurodegeneration — neuroprotective signaling in CNS injury models
ARA-290's ability to separate EPO's tissue protection from its blood production effects represents a genuine mechanistic innovation in cytoprotective research.
ARA-290 and EPO demonstrate the power of mechanistic dissection — one receptor pathway for cytoprotection, another for blood production, now separable in the lab.
| Aspect | ARA-290 | EPO (full) | BPC-157 |
|---|---|---|---|
| Receptor | IRR/βcR (cytoprotective) | EpoR homodimer + IRR | Not characterized |
| Erythropoiesis | None | Significant | None |
| Neuroprotection | Strong — SFN data | Indirect | Strong — various models |
| Clinical Data | Phase 2 (SFN, neuropathy) | Approved (anemia) | Extensive preclinical |
| Best Research Use | Neuroprotection, cytoprotection | Not for cytoprotection research | Repair, cytoprotection |
The following reflects findings from published preclinical and clinical safety assessments where available.
Phase 2 clinical data in neuropathic pain — significant pain reduction in sarcoidosis-associated SFN
Non-erythropoietic — tissue protection without blood thickening or cardiovascular risk
Novel βcR mechanism — a distinct cytoprotective pathway not targeted by any other research compound
Relatively small evidence base — growing quickly but fewer studies than established repair peptides; Phase 3 data not yet available
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026